Brought to you by 
Nabi acquires Braintree's renal drug
03 Jan 2022
Executive Summary
Nabi Biopharmaceuticals (discovers, develops, manufactures, and sells immune system enhancing drugs) has acquired Braintree Laboratories' (prescription pharmaceuticals) PhosLo calcium acetate, an oral therapeutic marketed to control elevated phosphate levels (hyperphosphatemia) in patients with end-stage renal failure.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Nabi acquires Braintree's renal drug
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice